Related Experiment Video
Updated: Jun 17, 2026
04:56
Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)
Published on: August 4, 2023
Circulating procoagulant microparticles in acute pulmonary embolism: a case-control study.
Laurence Bal1, Stéphane Ederhy1, Emanuele Di Angelantonio1
1Cardiology Department, Saint-Antoine University and Medical School, France; Université Pierre et Marie Curie, Paris, France.
International Journal of Cardiology
|December 29, 2009
Summary
Circulating procoagulant microparticles (CPMPs) were elevated in acute pulmonary embolism (APE) patients. Platelet-derived microparticles (PMPs) were a key source, suggesting CPMPs may mediate cardiovascular risk factors in venous thrombosis.
Area of Science:
- Hematology
- Cardiovascular Medicine
- Thrombosis Research
Background:
- Hypercoagulability is a hallmark of acute pulmonary embolism (APE).
- Circulating microparticles, particularly procoagulant microparticles (CPMPs) and platelet-derived microparticles (PMPs), are implicated in thrombotic disorders.
- The specific contribution of CPMPs and PMPs to APE pathogenesis remains incompletely understood.
Purpose of the Study:
- To investigate the role of circulating procoagulant microparticles (CPMPs) in the hypercoagulability associated with acute pulmonary embolism (APE).
- To compare CPMP and PMP levels in APE patients versus control groups with and without cardiovascular risk factors.
- To determine the primary source of procoagulant microparticle release in APE.
Main Methods:
- Quantitative analysis of circulating procoagulant microparticles (CPMPs) and platelet-derived microparticles (PMPs).
- Comparison of microparticle concentrations between 45 APE patients and 45 controls without cardiovascular risk factors, and 45 controls with cardiovascular risk factors.
- Statistical analysis to assess significant differences and correlations.
Main Results:
- CPMP and PMP concentrations were significantly higher in APE patients compared to controls without cardiovascular risk factors.
- PMPs were identified as the main source of procoagulant microparticle release in APE.
- This correlation between PMPs and procoagulant activity diminished when APE patients were compared to controls with cardiovascular risk factors.
Conclusions:
- Circulating procoagulant microparticles (CPMPs) are elevated in patients with acute pulmonary embolism (APE).
- Platelet-derived microparticles (PMPs) are a significant contributor to procoagulant activity in APE.
- CPMPs may play a role in mediating cardiovascular risk factors in the context of venous thrombosis.
Related Concept Videos
01:19Pulmonary Embolism I: Introduction
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
01:29Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:27Pulmonary Embolism III: Nursing Management
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...